AAAAAA

   
Results: 1-19 |
Results: 19
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies
Authors: Treon, SP Mitsiades, C Mitsiades, N Young, G Doss, D Schlossman, R Anderson, KC
Citation: Sp. Treon et al., Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies, J IMMUNOTH, 24(3), 2001, pp. 263-271
CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia
Authors: Treon, SP Agus, TB Link, B Rodrigues, G Molina, A Lacy, MQ Fisher, DC Emmanouilides, M Richards, AI Clark, B Lucas, MS Schlossman, R Schenkein, D Lin, B Kimby, E Anderson, KC Byrd, JC
Citation: Sp. Treon et al., CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia, J IMMUNOTH, 24(3), 2001, pp. 272-279
Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma andother neoplasias
Authors: Mitsiades, N Mitsiades, CS Poulaki, V Anderson, KC Treon, SP
Citation: N. Mitsiades et al., Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma andother neoplasias, EXPERT OP I, 10(8), 2001, pp. 1521-1530
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
Authors: Mitsiades, CS Treon, SP Mitsiades, N Shima, Y Richardson, P Schlossman, R Hideshima, T Anderson, KC
Citation: Cs. Mitsiades et al., TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications, BLOOD, 98(3), 2001, pp. 795-804
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
Authors: Davies, FE Raje, N Hideshima, T Lentzsch, S Young, G Tai, YT Lin, B Podar, K Gupta, D Chauhan, D Treon, SP Richardson, PG Schlossman, RL Morgan, GJ Muller, GW Stirling, DI Anderson, KC
Citation: Fe. Davies et al., Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma, BLOOD, 98(1), 2001, pp. 210-216
Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis
Authors: Raje, N Kica, G Chauhan, D Zhang, YN Teoh, G Treon, SP Hideshima, T Deng, JH Gao, SJ Alsina, M Wally, J Davies, FE Tai, YT Pinkus, GS Pinkus, JL Skinner, M Comenzo, RL Anderson, KC
Citation: N. Raje et al., Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis, AMYLOID, 7(2), 2000, pp. 126-132
Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6
Authors: Hideshima, T Chauhan, D Teoh, G Raje, N Treon, SP Tai, YT Shima, Y Anderson, KC
Citation: T. Hideshima et al., Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6, CLIN CANC R, 6(3), 2000, pp. 1180-1189
Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens
Authors: Treon, SP Shima, Y Grossbard, ML Preffer, FI Belch, AR Pilarski, LM Anderson, KC
Citation: Sp. Treon et al., Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens, ANN ONCOL, 11, 2000, pp. 107-111
The use of rituximab in the treatment of malignant and nonmalignant plasmacell disorders
Authors: Treon, SP Anderson, KC
Citation: Sp. Treon et Kc. Anderson, The use of rituximab in the treatment of malignant and nonmalignant plasmacell disorders, SEMIN ONCOL, 27(6), 2000, pp. 79-85
Immunotherapeutic strategies for the treatment of plasma cell malignancies
Authors: Treon, SP Raje, N Anderson, KC
Citation: Sp. Treon et al., Immunotherapeutic strategies for the treatment of plasma cell malignancies, SEMIN ONCOL, 27(5), 2000, pp. 598-613
Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage
Authors: Tai, YT Teoh, G Lin, B Davies, FE Chauhan, D Treon, SP Raje, N Hideshima, T Shima, Y Podar, K Anderson, KC
Citation: Yt. Tai et al., Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage, J IMMUNOL, 165(11), 2000, pp. 6347-6355
Isolation and characterization of human multiple myeloma cell enriched populations
Authors: Tai, YT Teoh, G Shima, Y Chauhan, D Treon, SP Raje, N Hideshima, T Davies, FE Anderson, KC
Citation: Yt. Tai et al., Isolation and characterization of human multiple myeloma cell enriched populations, J IMMUNOL M, 235(1-2), 2000, pp. 11-19
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy
Authors: Hideshima, T Chauhan, D Shima, Y Raje, N Davies, FE Tai, YT Treon, SP Lin, B Schlossman, RL Richardson, P Muller, G Stirling, DI Anderson, KC
Citation: T. Hideshima et al., Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy, BLOOD, 96(9), 2000, pp. 2943-2950
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma
Authors: Treon, SP Maimonis, P Bua, D Young, G Raje, N Mollick, J Chauhan, D Tai, YT Hideshima, T Shima, Y Hilgers, J von Mensdorff-Pouilly, S Belch, AR Pilarski, LM Anderson, KC
Citation: Sp. Treon et al., Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma, BLOOD, 96(9), 2000, pp. 3147-3153
CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines
Authors: Teoh, G Tai, YT Urashima, M Shirahama, S Matsuzaki, M Chauhan, D Treon, SP Raje, N Hideshima, T Shima, Y Anderson, KC
Citation: G. Teoh et al., CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines, BLOOD, 95(3), 2000, pp. 1039-1046
Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy
Authors: Treon, SP Shima, Y Preffer, FI Doss, DS Ellman, L Schlossman, RL Grossbard, ML Belch, AR Pilarski, LM Anderson, KC
Citation: Sp. Treon et al., Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy, SEMIN ONCOL, 26(5), 1999, pp. 97-106
Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells
Authors: Chauhan, D Bharti, A Raje, N Gustafson, E Pinkus, GS Pinkus, JL Teoh, G Hideshima, T Treon, SP Fingeroth, JD Anderson, KC
Citation: D. Chauhan et al., Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells, BLOOD, 93(5), 1999, pp. 1482-1486
Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detectionof Kaposi's sarcoma herpesvirus gene sequences
Authors: Raje, N Gong, JL Chauhan, D Teoh, G Avigan, D Wu, ZK Chen, DS Treon, SP Webb, IJ Kufe, DW Anderson, KC
Citation: N. Raje et al., Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detectionof Kaposi's sarcoma herpesvirus gene sequences, BLOOD, 93(5), 1999, pp. 1487-1495
Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone
Authors: Treon, SP Mollick, JA Urashima, M Teoh, G Chauhan, D Ogata, A Raje, N Hilgers, JHM Nadler, L Belch, AR Pilarski, LM Anderson, KC
Citation: Sp. Treon et al., Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone, BLOOD, 93(4), 1999, pp. 1287-1298
Risultati: 1-19 |